Cosentyx Denied by Insurance? How to Appeal

Cosentyx (secukinumab) is an IL-17A inhibitor with FDA approvals across six inflammatory conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. At $50,000–$80,000 per year, it is frequently denied on step therapy grounds. These denials are highly appealable when you present the right clinical evidence — ACR and ASAS-EULAR guidelines both recommend IL-17 inhibitors, and clinical trial data directly supports Cosentyx's effectiveness even after TNF inhibitor failure.

Why Insurers Deny Cosentyx

Insurance denials for Cosentyx follow predictable patterns that each require a targeted response.

TNF inhibitor step therapy. Plans require trial and failure of TNF inhibitors (adalimumab, etanercept, infliximab biosimilars) before approving IL-17 inhibitors. This is the most common denial reason, even when clinical guidelines support IL-17 therapy as a valid first-line biologic choice for certain patients.

Conventional therapy not completed. For psoriatic arthritis and ankylosing spondylitis, plans may require NSAID failure before biologics. For plaque psoriasis, topical therapy, phototherapy, or conventional systemics (methotrexate, cyclosporine) are often required first.

Severity criteria not met. For psoriasis, this typically means BSA below 10%, IGA below 3, or absence of special body site involvement. For AS and PsA, the insurer may claim disease activity is insufficient despite your symptoms and your physician's assessment.

Non-preferred IL-17 classification. Some plans prefer ixekizumab (Taltz) over secukinumab and require a formulary exception before approving Cosentyx.

How to Appeal a Cosentyx Denial

Step 1: Document Disease Severity with Objective Scores

For psoriasis: PASI score, BSA percentage, IGA score, and special body site involvement (scalp, nails, hands/feet, genitals). For PsA: swollen and tender joint count, CRP/ESR, enthesitis index, DAPSA or DAS28-CRP. For AS/nr-axSpA: BASDAI score (threshold ≥4), ASDAS-CRP (threshold ≥2.1), MRI evidence of sacroiliac joint inflammation (STIR edema), and CRP elevation. Validated scores are essential — subjective descriptions are easily dismissed.

Step 2: Document Prior Therapy Failures Completely

For each required step therapy drug, document: the agent tried, dates started and stopped, dose used, duration at adequate dose, and the specific reason for failure (lack of response, adverse effect, contraindication, or loss of response). Incomplete step therapy records are the single most common reason appealed Cosentyx denials fail. Under step therapy exception laws in California, New York, Texas, Illinois, and approximately 30 other states, your physician can invoke an exception when step therapy would delay effective treatment or cause harm.

Step 3: Have Your Specialist Write a Medical Necessity Letter

Your dermatologist or rheumatologist should explain why secukinumab is appropriate for your specific clinical profile, why required step therapy drugs are insufficient or inappropriate, and cite ACR, ASAS-EULAR, or AAD-NPF guidelines by name. The FUTURE trial series (PsA), MEASURE trials (AS), and CLEAR trial (psoriasis vs. ustekinumab) all provide strong published evidence supporting Cosentyx's clinical value.

Step 4: Request Peer-to-Peer Review

Within 72 hours of denial, request that your specialist speak directly with the insurer's medical director. Peer-to-peer conversations resolve a significant proportion of Cosentyx denials before a formal written appeal is even needed. Your specialist should reference ACR PsA 2021 guidelines, ASAS-EULAR AS 2022 recommendations, or AAD/NPF Psoriasis 2020 guidelines during this call.

Step 5: Submit the Formal Internal Appeal

Address each denial criterion point by point. Cite FUTURE/MEASURE/CLEAR trial data, guideline recommendations, and your state's step therapy exception law if applicable. Under the ACA (42 U.S.C. § 18022), prescription drugs are an essential health benefit and insurers must cover at least one drug in every pharmacological class.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">External Review

If the internal appeal is denied, request free external review by an independent specialist. External reviewers apply objective clinical standards — not the insurer's formulary preferences — and overturn biologics denials at meaningful rates. Request that the external reviewer be a board-certified rheumatologist or dermatologist with expertise in your specific condition.

What to Include in Your Appeal

• ICD-10 diagnosis codes (L40.0 plaque psoriasis, L40.50 psoriatic arthritis, M45.x ankylosing spondylitis)
• Objective disease activity scores (PASI, BSA, IGA, BASDAI, ASDAS-CRP, DAS28, DAPSA)
• Lab results (CRP, ESR, CBC, HBsAg/anti-HBc screening if required)
• MRI or X-ray reports documenting sacroiliac joint changes or erosions
• Complete prior therapy list with dates, doses, duration, and documented outcomes
• Specialist letter citing FUTURE, MEASURE, or CLEAR trial data and society guidelines
• Documentation of any contraindications to required step therapy drugs

Fight Back With ClaimBack

A Cosentyx denial does not have to be the final word. With the right clinical documentation — disease activity scores, step therapy failure records, and guideline citations from ACR and ASAS-EULAR — these denials are frequently overturned on appeal. Clinical trial evidence directly supporting secukinumab's effectiveness even after prior biologic failure gives your appeal strong scientific footing. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal